Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium

Core Viewpoint - Anixa Biosciences is advancing its ovarian cancer CAR-T technology, specifically the chimeric endocrine receptor-T cell (CER-T) therapy, which targets the follicle stimulating hormone receptor (FSHR) and is currently in a Phase 1 clinical trial [2][3][4]. Company Overview - Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4]. - The company also has a vaccine portfolio aimed at preventing triple negative breast cancer (TNBC) and ovarian cancer, along with other cancer vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [4]. Technology Details - The CAR-T technology being developed by Anixa is an autologous cell therapy that utilizes engineered T cells to specifically target FSHR, which is present on granulosa cells of the ovaries [2]. - This innovative approach is referred to as CER-T therapy, distinguishing it from traditional CAR-T therapies due to its targeting of a hormone receptor [2]. Clinical Development - Dr. Jose R. Conejo-Garcia will present the ongoing Phase 1 clinical trial results at the upcoming Ovarian Cancer Research Symposium, highlighting the safety and tolerability of the treatment, with some patients showing signs of tumor necrosis [3].